Effect of aspirin on deaths associated with sepsis in healthy older people (ANTISEPSIS): a randomised, double-blind, placebo-controlled primary prevention trial
Damon P Eisen, Karin Leder, Robyn L Woods, Jessica E Lockery, Sarah L McGuinness, Rory Wolfe, David Pilcher, Elizabeth M Moore, Adithya Shastry, Mark R Nelson, Christopher M Reid, John J McNeil, Emma S McBryde
LANCET RESPIRATORY MEDICINE | ELSEVIER SCI LTD | Published : 2021
BACKGROUND: Sepsis is a serious global health issue and a major cause of death and disability. The availability of a simple, community-based preventive strategy could substantially reduce the burden of sepsis. We aimed to establish whether low-dose aspirin reduced deaths or hospital admissions associated with sepsis in older people. METHODS: ANTISEPSIS was a substudy of ASPREE (a randomised controlled primary prevention trial of low-dose aspirin [100 mg per day] compared with placebo in community dwelling older adults conducted in Australia and the USA), with the Australian cohort included in the ANTISEPSIS substudy. Inclusion criteria were participants aged at least 70 years who did not hav..View full abstract
National Health and Medical Research Council of Australia, National Institutes of Health, Monash University.